MTOR and breast cancer: In vitro studies in canine mammary cancer cell lines show that cSrc influences these pathways and so combination therapies of cSrc and mTOR inhibitors, or direct targeting of P4 or GH signaling are therefore possible new targets for therapeutic interventions.